EMA requests comment on final biosimilar guidance

June 14, 2013 10:01 AM

The European Medicines Agency has released a revision of the guideline addressing the clinical and non-clinical issues related to similar biological products (biosimilars) containing biotechnology-derived proteins as the active substance for a six-month public consultation.

The document lays down the non-clinical and clinical requirements for marketing authorisation of a biosimilar claiming to be similar to a biological product already marketed.

This guideline updates the previous guidance, which came into effect in 2006. Since then, 14 biosimilar medicines have received marketing authorisation in the European Union and the number of scientific-advice requests received by theCommittee for Medicinal Products for Human Use (CHMP) on the development of biosimilar medicines has increased significantly.

On the basis of the experience gained since the release of the initial guideline, the revision provides additional guidance on the following topics:

  • the risk-based approach for the design of non-clinical studies;
  • the use of pharmacodynamic markers for the demonstration of clinical comparability;
  • study design (non-inferiority versus equivalence), choice of an appropriate patient population and choice of surrogate endpoints in efficacy trials;
  • the design of immunogenicity studies;
  • extrapolation of efficacy and safety from one therapeutic indication to another.

This guideline is one of three overarching biosimilar guidelines, which are complemented by product-specific biosimilar guidelines. The other two overarching guidelines are:


Source: EMA

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!